SPRY 10.07 ▼ -5.80% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    ARS Pharmaceuticals Inc.

    NASDAQ: SPRY · Real-Time Price · USD
    10.07
    -0.62 (-5.80%)
    At close: Sep 05, 2025, 3:59 PM
    10.37
    2.98%
    After-hours: Sep 05, 2025, 07:57 PM EDT
    -5.80%
    Bid 10.02
    Market Cap 983.7M
    Revenue (ttm) 112.34M
    Net Income (ttm) -48.02M
    EPS (ttm) -0.48
    PE Ratio (ttm) -20.98
    Forward PE -13.6
    Analyst Buy
    Ask 10.51
    Volume 5,136,046
    Avg. Volume (20D) 1,842,203
    Open 10.70
    Previous Close 10.69
    Day's Range 9.97 - 10.73
    52-Week Range 9.97 - 18.90
    Beta 0.92

    About SPRY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SPRY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SPRY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    ARS Pharmaceuticals Inc. is scheduled to release its earnings on Nov 12, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 weeks ago
    -5.04%
    ARS Pharmaceuticals shares are trading lower follo... Unlock content with Pro Subscription
    3 months ago
    +11.48%
    ARS Pharmaceuticals shares are trading higher on possible continued strength after reporting a Q1 revenue beat earlier mid-week.
    news image

    3 weeks ago · seekingalpha.com

    ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

    ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Eric Karas - Chief Commercial Officer Justin Chakma - Chief Business Officer K...

    news image

    3 weeks ago · zacks.com

    ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

    ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.13 per share a year ago.

    news image

    1 month ago · zacks.com

    Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for

    ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · zacks.com

    ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?

    Does ARS Pharmaceuticals, Inc. (SPRY) have what it takes to be a top stock pick for momentum investors? Let's find out.

    news image

    1 month ago · zacks.com

    Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?

    The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...

    news image

    1 month ago · zacks.com

    What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'

    ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma...

    Add to Watchlist